Christine I Wooddell received her Graduate training in Cell and Molecular Biology with an emphasis on transcription and gene regulation. She then worked on development of gene therapy at Mirus Bio, first on the development of therapeutic gene expression vectors and then on delivery of gene therapy for Duchenne muscular dystrophy. Mirus Bio was acquired by Hoffmann-La Roche and then by Arrowhead Pharmaceuticals. She is now the Director of Liver Targeting at Arrowhead where she leads the preclinical research group to develop liver-targeted therapeutics using animal models. Since 2011 her research has focused on the development of RNA interference therapeutics to treat chronic hepatitis B virus infection and liver disease associated with alpha-1 antitrypsin deficiency (AATD). ARC-520 and ARC-521 were developed to treat HBV infection and ARC-AAT to treat AATD liver disease. These three drugs have been advanced to Phase 2 clinical trials. c Christine I Wooddell received her Graduate training in Cell and Molecular Biology with an emphasis on transcription and gene regulation. She then worked on development of gene therapy at Mirus Bio, first on the development of therapeutic gene expression vectors and then on delivery of gene therapy for Duchenne muscular dystrophy. Mirus Bio was acquired by Hoffmann-La Roche and then by Arrowhead Pharmaceuticals. She is now the Director of Liver Targeting at Arrowhead where she leads the preclinical research group to develop liver-targeted therapeutics using animal models. Since 2011 her research has focused on the development of RNA interference therapeutics to treat chronic hepatitis B virus infection and liver disease associated with alpha-1 antitrypsin deficiency (AATD). ARC-520 and ARC-521 were developed to treat HBV infection and ARC-AAT to treat AATD liver disease. These three drugs have been advanced to Phase 2 clinical trials. c

development of RNA interference therapeutics to treat chronic hepatitis B virus infection and liver disease associated with alpha-1 antitrypsin deficiency (AATD). ARC-520 and ARC-521 were developed to treat HBV infection and ARC-AAT to treat AATD liver disease